Circumventing melanoma chemoresistance by targeting DNA repair
- PMID: 22788765
- DOI: 10.2174/092986712802002509
Circumventing melanoma chemoresistance by targeting DNA repair
Abstract
Available evidence demonstrates that the DNA repair machinery is involved in melanoma resistance to chemotherapeutics. Furhtermore, preclinical findings suggest that interfering with DNA repair could increase chemosensitivity of melanoma cells. However, the clinical implementation of these principles is still in its infancy and no such strategy is currently proven to be effective in patients with advanced melanoma. Since the molecular mechanisms governing the relationship between chemoresistance and DNA repair are not fully elucidated, more basic and translational research is needed to understand the reasons for the failures and to identify novel targets. In this review we summarize the experimental and clinical findings that are fostering the research in this promising field of oncology.
Similar articles
-
Modulation of the efficacy of temozolomide and dacarbazine melanoma treatment by DNA-repair factors in vivo and in vitro.Int J Clin Pharmacol Ther. 2009 Jan;47(1):33-5. doi: 10.5414/cpp47033. Int J Clin Pharmacol Ther. 2009. PMID: 19203531 No abstract available.
-
[Effectiveness of DNA repair and expression of MLH1, MSH2 and FASR in lymphocytes of patients with chemotherapy-responsive, disseminated cutaneous melanoma].Vopr Onkol. 2011;57(2):165-72. Vopr Onkol. 2011. PMID: 21809660 Russian.
-
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5418-25. doi: 10.1158/1078-0432.CCR-07-0418. Clin Cancer Res. 2007. PMID: 17875772
-
MYC, PARP1, and chemoresistance: BIN there, done that?Sci Signal. 2011 Mar 29;4(166):pe15. doi: 10.1126/scisignal.2001946. Sci Signal. 2011. PMID: 21447796 Review.
-
DNA repair pathways in drug resistance in melanoma.Anticancer Drugs. 2004 Jun;15(5):421-6. doi: 10.1097/01.cad.0000127665.74096.93. Anticancer Drugs. 2004. PMID: 15166615 Review.
Cited by
-
Protocatechuic aldehyde sensitizes BRAF-mutant melanoma cells to temozolomide through inducing FANCD2 degradation.Med Oncol. 2025 Jan 18;42(2):48. doi: 10.1007/s12032-025-02601-y. Med Oncol. 2025. PMID: 39824992
-
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).BMC Cancer. 2018 May 10;18(1):552. doi: 10.1186/s12885-018-4479-2. BMC Cancer. 2018. PMID: 29747595 Free PMC article. Clinical Trial.
-
Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutation.PLoS One. 2014 Dec 1;9(12):e112025. doi: 10.1371/journal.pone.0112025. eCollection 2014. PLoS One. 2014. PMID: 25437182 Free PMC article.
-
Long non-coding RNA CCHE1 modulates LDHA-mediated glycolysis and confers chemoresistance to melanoma cells.Cancer Metab. 2023 Jul 21;11(1):10. doi: 10.1186/s40170-023-00309-z. Cancer Metab. 2023. PMID: 37480145 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical